Central Pharmaceutical JSC No3 banner
C

Central Pharmaceutical JSC No3
VN:DP3

Watchlist Manager
Central Pharmaceutical JSC No3
VN:DP3
Watchlist
Price: 62 300 VND -0.64% Market Closed
Market Cap: ₫1.3T

Wall St Price Targets

DP3 Price Targets Summary
Central Pharmaceutical JSC No3

There are no price targets for DP3.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Central Pharmaceutical JSC No3 Competitors:
Price Targets
U10
UOB-Kay Hian Holdings Ltd
35% Upside
OBT
Orange County Bancorp Inc
8% Upside
KRUS
Kura Sushi USA Inc
52% Upside

Revenue
Forecast

8% / Year
Past Growth
-100% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
8% / Year
Past Growth
-100% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 10 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 1 year is -100%.

Gross Profit
Forecast

11% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
11% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Central Pharmaceutical JSC No3

Operating Income
Forecast

22% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
22% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Operating Income Forecast
is not available for Central Pharmaceutical JSC No3

Pre-Tax Income
Forecast

25% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
25% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Central Pharmaceutical JSC No3

Net Income
Forecast

25% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
25% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Net Income Forecast
is not available for Central Pharmaceutical JSC No3
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is DP3's stock price target?
Not Available

DP3 does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Central Pharmaceutical JSC No3?
Projected CAGR
-100%

Over the last 10 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 1 year is -100%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett